Bristol-Myers Squibb Company

NYSE:BMY Stock Report

Market Cap: US$107.7b

Bristol-Myers Squibb Valuation

Is BMY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BMY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BMY ($54.23) is trading below our estimate of fair value ($137.51)

Significantly Below Fair Value: BMY is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BMY?

Other financial metrics that can be useful for relative valuation.

BMY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA7.4x
PEG Ratio1.8x

Price to Earnings Ratio vs Peers

How does BMY's PE Ratio compare to its peers?

The above table shows the PE ratio for BMY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.8x
ZTS Zoetis
33.1x8.1%US$77.2b
PFE Pfizer
73.6x20.6%US$157.3b
JNJ Johnson & Johnson
28.6x9.5%US$380.6b
RPRX Royalty Pharma
12x5.9%US$18.2b
BMY Bristol-Myers Squibb
13.7x7.8%US$107.7b

Price-To-Earnings vs Peers: BMY is good value based on its Price-To-Earnings Ratio (13.7x) compared to the peer average (36.8x).


Price to Earnings Ratio vs Industry

How does BMY's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: BMY is good value based on its Price-To-Earnings Ratio (13.7x) compared to the US Pharmaceuticals industry average (19.8x).


Price to Earnings Ratio vs Fair Ratio

What is BMY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BMY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.7x
Fair PE Ratio28.5x

Price-To-Earnings vs Fair Ratio: BMY is good value based on its Price-To-Earnings Ratio (13.7x) compared to the estimated Fair Price-To-Earnings Ratio (28.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BMY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$54.23
US$56.41
+4.0%
13.3%US$75.00US$41.00n/a23
Mar ’25US$50.89
US$56.70
+11.4%
15.8%US$85.00US$41.00n/a22
Feb ’25US$48.67
US$60.66
+24.6%
16.7%US$85.00US$42.00n/a23
Jan ’25US$51.31
US$61.92
+20.7%
16.5%US$85.00US$42.00n/a23
Dec ’24US$50.10
US$64.13
+28.0%
17.0%US$90.00US$50.00n/a24
Nov ’24US$51.28
US$65.60
+27.9%
16.0%US$90.00US$50.00n/a23
Oct ’24US$58.04
US$72.47
+24.9%
13.0%US$90.00US$55.00n/a23
Sep ’24US$62.02
US$72.83
+17.4%
13.4%US$90.00US$56.00n/a24
Aug ’24US$61.53
US$73.21
+19.0%
13.6%US$92.00US$56.00n/a24
Jul ’24US$63.95
US$78.64
+23.0%
12.4%US$92.00US$59.00n/a22
Jun ’24US$64.68
US$79.05
+22.2%
12.4%US$92.00US$59.00n/a21
May ’24US$68.40
US$78.74
+15.1%
11.8%US$92.00US$59.00n/a21
Apr ’24US$69.31
US$80.00
+15.4%
11.4%US$95.00US$62.00n/a21
Mar ’24US$69.36
US$81.47
+17.5%
10.9%US$95.00US$62.00US$50.8919
Feb ’24US$71.23
US$81.10
+13.9%
11.0%US$95.00US$60.00US$48.6719
Jan ’24US$71.95
US$79.73
+10.8%
10.9%US$92.00US$60.00US$51.3119
Dec ’23US$80.88
US$79.26
-2.0%
10.4%US$90.00US$60.00US$50.1019
Nov ’23US$77.70
US$79.22
+2.0%
10.6%US$90.00US$60.00US$51.2818
Oct ’23US$71.09
US$80.32
+13.0%
10.6%US$94.00US$61.00US$58.0419
Sep ’23US$69.09
US$80.42
+16.4%
10.0%US$92.00US$61.00US$62.0219
Aug ’23US$73.62
US$80.36
+9.2%
10.0%US$92.00US$61.00US$61.5319
Jul ’23US$76.84
US$79.05
+2.9%
10.1%US$92.00US$63.00US$63.9519
Jun ’23US$74.96
US$78.80
+5.1%
10.3%US$94.00US$63.00US$64.6821
May ’23US$75.27
US$76.93
+2.2%
9.8%US$94.00US$64.00US$68.4021
Apr ’23US$73.82
US$75.12
+1.8%
9.1%US$94.00US$65.00US$69.3121
Mar ’23US$68.63
US$72.93
+6.3%
9.2%US$94.00US$61.00US$69.3621

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.